Free Newsletter
Merck KGaA budgets $1.58B for drug R&D
With about 40 drug development projects in the pipeline, Germany's Merck KGaA says it will spend about €1 billion ($1.58 billion) on drug research this year. That R&D budget represents about 22 percent of sales and is a big increase on last year's budget of €890 million. Merck officials say they're out to sell their diabetes research division, and plan to focus on four key areas: cancer, infertility, nervous system and autoimmune diseases.
- check out the AFX report
Related Articles:
Merck KGaA CEO eyes new acquisitions
Mylan inks $6.6B deal for Merck's generic drug biz
Merck KGaA buying control of Serono
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: